We are live on ! Find out more
KLRS

Kalaris Therapeutics
KLRS

71 hedge funds and large institutions have $33.9M invested in Kalaris Therapeutics in 2024 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 25 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

10,000% more call options, than puts

Call options by funds: $202K | Put options by funds: $2K

0.11% less ownership

Funds ownership: 1.88% → 1.77% (-0.11%)

7% less funds holding

Funds holding: 76 → 71 (-5)

7% less capital invested

Capital invested by funds: $36.4M → $33.9M (-$2.53M)

26% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 19

36% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 25

Holders
71
Holders Change
-5
Holders Change %
-6.58%
% of All Funds
1.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
16
Reduced
25
Closed
19
Calls
$202K
Puts
$2K
Net Calls
+$200K
Net Calls Change
-$199K

Top Buyers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
+$4.3M
2
RC
RBF Capital
California
+$345K
3
BCM
BML Capital Management
Indiana
+$309K
4
Millennium Management
Millennium Management
New York
+$271K
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$258K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$2.11M
2
ICM
Irenic Capital Management
New York
-$1.95M
3
State Street
State Street
Massachusetts
-$734K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$481K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$316K
Name Holding Trade Value Shares
Change 		Change in
Stake
AllianceBernstein
76
AllianceBernstein
Tennessee
– -$48.6K -2,801 Closed
Verition Fund Management
77
Verition Fund Management
Connecticut
– -$48.2K -2,775 Closed
Amundi
78
Amundi
France
– -$33.7K -1,976 Closed
Barclays
79
Barclays
United Kingdom
– -$26.6K -1,532 Closed
Capstone Investment Advisors
80
Capstone Investment Advisors
New York
– -$20.6K -1,185 Closed
Manulife (Manufacturers Life Insurance)
81
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$16.1K -928 Closed
Principal Financial Group
82
Principal Financial Group
Iowa
– -$15.7K -901 Closed
Wells Fargo
83
Wells Fargo
California
– -$13.8K -794 Closed
SG Americas Securities
84
SG Americas Securities
New York
– -$13K -765 Closed
Mirae Asset Global Investments
85
Mirae Asset Global Investments
South Korea
– -$48.6K -527 Closed
Invesco
86
Invesco
Georgia
– -$8.99K -518 Closed
Legal & General Group
87
Legal & General Group
United Kingdom
– -$3.04K -175 Closed
QT
88
Quantbot Technologies
New York
– -$2.46K -142 Closed
AIP
89
Ameritas Investment Partners
Nebraska
– -$1.82K -105 Closed
AB
90
Amalgamated Bank
New York
– -$1K -45 Closed
AWM
91
Avior Wealth Management
Nebraska
– -$6 – –
1 2 3
4

KLRS Hedge Fund Activity: Q2 2024 in Review

71 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q2 2024, worth a combined $33.9M — down 7% from $36.4M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of KLRS and 14 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 16 added.

The largest buyer was Octagon Capital Advisors, adding an estimated $4.3M. The largest seller was BlackRock, cutting an estimated $2.11M.

  • 71 institutional investors held Kalaris Therapeutics (KLRS) as of Q2 2024, down from 76 in Q1 2024.
  • Funds reported $33.9M of Kalaris Therapeutics stock for Q2 2024, down 7% quarter-over-quarter.
  • 14 funds opened new Kalaris Therapeutics positions in Q2 2024 and 19 closed out, a net change of -5 holders.
  • The largest Kalaris Therapeutics buyer in Q2 2024 was Octagon Capital Advisors, an estimated $4.3M added.
  • The largest Kalaris Therapeutics seller in Q2 2024 was BlackRock, an estimated $2.11M sold.

Based on aggregated 13F filings for Q2 2024.